Actinium-225

SpectronRx and RLS Team Up to Give the Radiopharmaceutical Pipeline and Supply Chain a Much-Needed Boost

Retrieved on: 
Mercoledì, Giugno 7, 2023
Partnership, Drug development, ISO, Radiopharmaceutical, Cancer, Research, EMA, Nuclear medicine, Patient, QA, Medicine, RLS, Quality control, Nuclear pharmacy, FDA, Health, Actinium-225, Safety, Medical imaging

INDIANAPOLIS and LAKE ZURICH, Ill., June 7, 2023 /PRNewswire/ -- SpectronRx, a leading radiopharmaceutical developer and manufacturer, and RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the US, today announced an agreement that will significantly enhance the supply and availability of diagnostic and therapeutic radiopharmaceuticals. With this collaboration, both companies hope to further bridge the gap between drug development, manufacturing, distribution and patient care by improving production and increasing the availability of life-saving medicines. 

Key Points: 
  • "Radiopharmaceuticals are essential to diagnosing and treating diseases ranging from cancer to neurodegenerative disorders," said SpectronRx CEO John Zehner.
  • As part of the agreement, SpectronRx will manufacture radiopharmaceutical products for RLS and other partners, and RLS will distribute them.
  • "Critical for patient care, some of the most effective radiopharmaceutical treatments are in limited supply," said SpectronRx President Anwer Rizvi.
  • SpectronRx has three distinct specialties: Radiopharmaceutical Contract Development (rCDMO), Radiopharmaceutical Contract Manufacturing (rCMO), and Isotope Production.

POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Lunedì, Maggio 15, 2023
GMP, Partnership, Investment, Food, Clinical trial, Radiopharmaceutical, SPLASH, Fast Track, Research, Development, CGMP, Administration, University Health Network, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Facility, Actinium-225, Prostate cancer, Rare-earth element, Pharmaceutical industry, Cryptocurrency

INDIANAPOLIS, May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

Key Points: 
  • Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer, Ionetix Alpha Corp.
    INDIANAPOLIS, May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.
  • “As excitement in the clinical and commercial potential of radiopharmaceuticals grows, POINT continues to expand the breadth and depth of our next-generation radioligand platform,” said Joe McCann, Ph.D., CEO of POINT Biopharma.
  • For our late-stage programs, we invested further in ensuring manufacturing scalability by securing additional reactor access necessary for the production of lutetium-177 isotope.
  • Enrollment in PNT2002's SPLASH trial (NCT04647526) is complete and top line data are expected in the second half of 2023.

POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer

Retrieved on: 
Lunedì, Maggio 15, 2023
GMP, Good, Good manufacturing practice, Cyclotron, Patient, Isotope, Actinium-225, Pharmaceutical industry

Ionetix-, a new subsidiary of IONETIX, is focused on near-term, commercial-scale production of Good Manufacturing Practice (GMP) grade therapeutic isotopes, such as actinium-225 (225Ac).

Key Points: 
  • Ionetix-, a new subsidiary of IONETIX, is focused on near-term, commercial-scale production of Good Manufacturing Practice (GMP) grade therapeutic isotopes, such as actinium-225 (225Ac).
  • “Access to GMP grade therapeutic isotopes like 225Ac continues to be a key rate-limiting factor in the clinical development of next generation radioligands,” said Dr. Joe McCann, Chief Executive Officer of POINT.
  • Ionetix- will initially produce and distribute 225Ac from its isotope production and manufacturing facility located in Lansing, Michigan.
  • This first-of-its kind facility is highly specialized and dedicated exclusively to the production and distribution of alpha-emitting radionuclides using cyclotrons.

NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Guggenheim Radiopharmaceuticals Day

Retrieved on: 
Martedì, Maggio 9, 2023
Cardiology, Radiology, Biotechnology, Pharmaceutical, Oncology, Health, Health Technology, Other Health, NorthStar, Radiopharmaceutical, Growth, CDMO, Radionuclide, Actinium-225, Tourism, Medical imaging

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that it will be participating in the upcoming 2023 Guggenheim Radiopharmaceuticals Day.

Key Points: 
  • NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that it will be participating in the upcoming 2023 Guggenheim Radiopharmaceuticals Day.
  • Stephen Merrick, Chief Executive Officer of NorthStar, will be part of a panel discussion featuring leading companies focused on large-scale production of radioisotopes and CDMO suppliers, beginning at 12:00 p.m.
  • “NorthStar continues to expand our leadership position in the rapidly growing area of therapeutic and diagnostic radioisotopes, radiopharmaceuticals, and radiopharmaceutical contract development manufacturing organization (CDMO/CMO) services,” said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
  • “Our company is poised to be the first commercial-scale producer of therapeutic radioisotopes copper-67 and non-carrier added (n.c.a.)

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

Retrieved on: 
Giovedì, Aprile 27, 2023
ITM, Therapy, Research group, TRT, PSI, Cancer, Auger, Research, Radiopharmaceutical, Doctor of Philosophy, Paul Scherrer Institute, Hospital, Patient, TRT1, Actinium-225, Pharmaceutical industry, Medical imaging

The partners will combine their respective technologies and expertise in the production of terbium-161 including clinical and commercial use in Targeted Radionuclide Therapy (TRT) for the treatment of cancer.

Key Points: 
  • The partners will combine their respective technologies and expertise in the production of terbium-161 including clinical and commercial use in Targeted Radionuclide Therapy (TRT) for the treatment of cancer.
  • This collaboration significantly expands ITM’s production and development portfolio for medical isotopes in precision oncology.
  • Terbium-161 has been identified as a very promising therapeutic isotope for TRT1 in cancer based on its outstanding physico-chemical properties.
  • Terbium-161’s potential as a next-generation radioisotope is based on its unique ability to emit both medium-range beta radiation and short-range Auger electrons.

Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting

Retrieved on: 
Mercoledì, Aprile 19, 2023
Actinium, AACR, HER3, ARC, Actinium-225, American Association for Cancer Research, Drug resistance, Malignancy, Cancer, Annual general meeting, Poster, NYSE, Vaccine

NEW YORK, April 19, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announces encouraging preclinical proof of concept data at a poster presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting being held April 14 - 19, 2023 in Orlando, Florida. The poster showcased the robust anti-tumor effects of HER3-targeted radiotherapy using multiple therapeutic radionuclides in preclinical models of high unmet need malignancies.

Key Points: 
  • The poster showcased the robust anti-tumor effects of HER3-targeted radiotherapy using multiple therapeutic radionuclides in preclinical models of high unmet need malignancies.
  • "The new data from our HER3 program once again demonstrate the potent anti-tumor effect and broad utility of targeted radiotherapy in solid tumors.
  • Building on our prior results in lung cancer models, we are excited by the highly significant reduction in tumor burden seen in ovarian cancer and colorectal cancer models, providing much improved treatment options to critical patients with poor clinical outcomes.
  • HER3 is a member of the EGFR family, a highly validated cancer target for which there are several approved therapies directed against EGFR and/or HER2.

Convergent Therapeutics Announces Updates on its Lead Therapeutic Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Lunedì, Aprile 17, 2023
Neutropenia, AACR, Hematology, PSMA, Convergent, American Association for Cancer Research, Xerostomia, Oncology, Weill Cornell Medical Center, Sandra, Assistant, CTC, Weill Cornell Medicine, Cornell University, Patient, Division, Anemia, NewYork-Presbyterian Hospital, Therapy, AST, Safety, PSA, Thrombocytopenia, Actinium-225, Fatigue, Prostate cancer, Vaccine, Pharmaceutical industry, Medicine

The title of the presentation is "Phase I dose-escalation study of fractionated dose 225Ac-J591 for metastatic castration resistant prostate cancer."

Key Points: 
  • The title of the presentation is "Phase I dose-escalation study of fractionated dose 225Ac-J591 for metastatic castration resistant prostate cancer."
  • This presentation will focus on safety and efficacy data from a Weill Cornell Medicine-sponsored phase I/II dose-escalation study (NCT04506567) in patients with metastatic castration resistant prostate cancer.
  • We are excited by the potential of 225Ac-J591 for treatment of patients with metastatic castration resistant prostate cancer."
  • "We are continuing to advance CONV01-α (225Ac−J591) as an impactful therapeutic to fill an unmet need in prostate cancer."

EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

Retrieved on: 
Sabato, Aprile 15, 2023
GMP, Medicine, Radionuclide, PSMA, Actinium-225, TecDAX, Research, Radiopharmaceutical, ISIN, Medical imaging

Berlin, Germany and Indianapolis, Indiana, USA – 4 April 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225).

Key Points: 
  • Berlin, Germany and Indianapolis, Indiana, USA – 4 April 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225).
  • Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands.
  • Eckert & Ziegler is currently developing a production process to be capable of supplying significant amounts of the highly demanded radionuclide Ac-225 to the market.
  • “This agreement with Eckert & Ziegler contributes to our continued research and development with Actinium-225, an exciting therapeutic isotope.

Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

Retrieved on: 
Martedì, Aprile 4, 2023
GMP, Medicine, Radionuclide, PSMA, Actinium-225, TecDAX, Research, Radiopharmaceutical, ISIN, Medical imaging

BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) -- Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225).

Key Points: 
  • BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) -- Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225).
  • Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands.
  • Eckert & Ziegler is currently developing a production process to be capable of supplying significant amounts of the highly demanded radionuclide Ac-225 to the market.
  • “This agreement with Eckert & Ziegler contributes to our continued research and development with Actinium-225, an exciting therapeutic isotope.

NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies

Retrieved on: 
Mercoledì, Aprile 12, 2023
Biotechnology, Technology, Other Health, Health, Radiology, Pharmaceutical, Oncology, Health Technology, Other Technology, Medical Devices, Hardware, Curium, Business development, University of St. Francis, University, Health administration, Jacksonville State University, Radionuclide, Radiopharmaceutical, Cardinal, MBA, Multimedia, NorthStar, Nuclear medicine, Cardinal Health, Business administration, CDMO, Patient, Master of Business Administration, Knowledge, Growth, MHA, Actinium-225, Medical imaging, Management

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies.

Key Points: 
  • NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies.
  • Mr. Vinyard, who has been with NorthStar since 2021, was previously Senior Director, Business Development, Therapeutic Technologies, for the Company.
  • In this new position, Mr. Vinyard will have responsibility to advance the successful commercialization and market implementation of therapeutic radioisotopes, including copper-67 (Cu-67) and non-carrier added (n.c.a.)
  • View the full release here: https://www.businesswire.com/news/home/20230412005134/en/
    NorthStar Medical Radioisotopes has promoted Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies.